Sana Biotechnology Files Q1 2025 10-Q

TL;DR

Sana Bio's Q1 2025 10-Q is in. Check financials, stock, and warrants.

AI Summary

Sana Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including references to various agreements and financial instruments such as common stock, pre-funded warrants, and employee stock options. The company's principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, WA.

Why It Matters

This filing provides investors with an update on Sana Biotechnology's financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — Biotechnology companies often carry higher risk due to the nature of research and development, regulatory hurdles, and market volatility.

Key Numbers

• 2025-03-31 — Reporting Period End Date (Indicates the financial period covered by the report.)
• 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Sana Biotechnology, Inc. (company) — Filer of the 10-Q
• 20250331 (date) — End of reporting period
• 20250508 (date) — Filing date
• 188 East Blaine Street, Suite 400, Seattle, WA 98102 (address) — Company business and mailing address
• Beam Therapeutics Incorporated (company) — Mentioned in relation to a date
• Cobalt Biomedicine Inc (company) — Mentioned in relation to an acquisition agreement

FAQ

From the Filing

0000950170-25-066943.txt : 20250508 0000950170-25-066943.hdr.sgml : 20250508 20250508161002 ACCESSION NUMBER: 0000950170-25-066943 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc. CENTRAL INDEX KEY: 0001770121 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39941 FILM NUMBER: 25926121 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 701-7914 MAIL ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 10-Q 1 sana-20250331.htm 10-Q 10-Q Q1 false --12-31 0001770121 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001770121 sana:HarvardCollegeMember srt:MaximumMember 2019-03-01 2019-03-31 0001770121 sana:BeamTherapeuticsIncorporatedMember srt:MaximumMember 2021-10-31 0001770121 stpr:CA sana:OfficeAndLaboratoryMember 2025-01-01 2025-03-31 0001770121 srt:ParentCompanyMember sana:MarketCapitalizationTwoMember 2019-02-28 0001770121 sana:AcquisitionAgreementMember sana:CobaltBiomedicineIncMember srt:MinimumMember 2019-02-28 0001770121 sana:MilestoneTwoMember sana:HarvardCollegeMember 2019-03-31 0001770121 us-gaap:CommonStockMember 2023-12-31 0001770121 sana:PreFundedWarrantsMember 2024-01-01 2024-03-31 0001770121 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001770121 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001770121 us-gaap:FairValueInputsLevel3Member sana:SuccessPaymentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember sana:LongTermFinancialLiabilitiesMember 2025-03-31 0001770121 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001770121 sana:HarvardCollegeMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001770121 us-gaap:CommonStockMember 2024-03-31 0001770121 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member sana:ShortTermMarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001770121 us-gaap:FairValueInputsLevel3Member sana:SuccessPaymentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember sana:LongTermFinancialLiabilitiesMember 2024-12-31 0001770121 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001770121 sana:HarvardCollegeMember sana:MilestoneFiveMember 2019-03-01 2019-03-31 0001770121 sana:HarvardCollegeMember sana:MilestoneFiveMember 2019-03-31 0001770121 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001770121 sana:AtTheMarketFacilityMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001770121 sana:BothellWashingtonMember sana:OfficeLaboratoryAndManufacturingMember 2025-01-01 2025-03-31 0001770121 sana:HarvardCollegeMember sana:MilestoneFourMember 2019-03-01 2019-03-31 0001770121 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001770121 sana:CobaltBiomedicineIncMember 2025-01-01 2025-03-31 0001770121 us-gaap:CommonStockMember 2024-12-31 0001770121 us-gaap:MeasurementInputPriceVolatilityMember sana:CobaltSuccessPaymentLiabilityMember 2024-12-31 0001770121 us-gaap:OverAllotmentOptionMember 2024-02-29 0001770121 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001770121 2024-01-01 2024-03-31 0001770121 sana:CobaltContingentConsiderationLiabilityMember 2025-01-01 2025-03-31 0001770121 sana:AtTheMarketFacilityMember 2024-01-01 2024-03-31 0001770121 sana:CowenAndCompanyLLCMember sana:AtTheMarketFacilityMember us-gaap:SubsequentEventMember 2025-05-08 0001770121 srt:WeightedAverageMember sana:CobaltContingentConsiderationLiabilityMember sana:MeasurementInputProbabilityOfMilestoneAchievementMember 2024-12-31 0001770121 sana:CobaltBiomedicineIncMember sana:AcquisitionAgreementM